Skip to main content

Advertisement

SpringerLink
Log in

Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Oral bisphosphonates are widely used for fracture prevention, but there is a concern regarding potential adverse cardiovascular effects of bisphosphonates. In this large, population-based case-control study, we found no evidence of an association between bisphosphonate use and risk of venous thromboembolism (VTE).

Introduction

We examined the relation between the use of oral bisphosphonates for osteoporosis and the risk of VTE.

Methods

We conducted a population-based case-control study in Northern Denmark (population, 1.7 million). Using the Danish National Registry of Patients, we identified all women with a first-time hospital diagnosis of VTE between 1999 and 2006. For each case, we selected up to ten female population controls, matched on date of the index VTE event and age. Data on use of oral bisphosphonates, other medications, and comorbidity were obtained from medical databases. We used logistic regression to estimate odds ratios (OR) for VTE associated with bisphosphonate users while adjusting for potential confounding factors.

Results

Four thousand one hundred ninety-three cases and 41,197 controls were included in the study. One hundred forty-nine cases (3.6%) and 1,078 controls (2.6%) were current bisphosphonate users. The adjusted OR for VTE among the current bisphosphonate users compared with nonusers was 1.03 (95% confidence interval (CI): 0.84–1.26), and when restricted to cases of unprovoked thromboembolism, the adjusted OR was 1.08 (95% CI: 0.82–1.42). There was no association either for pulmonary embolism or for deep venous thrombosis.

Conclusion

We found no evidence of an association of oral bisphosphonate use with the risk of VTE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428

    Article  CAS  PubMed  Google Scholar 

  2. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  3. Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation. N Engl J Med 356:1895–1896

    Article  CAS  PubMed  Google Scholar 

  4. Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712–713

    CAS  PubMed  Google Scholar 

  5. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–809

    Article  CAS  PubMed  Google Scholar 

  6. Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813–816

    Article  PubMed  Google Scholar 

  7. Fowkes FJ, Price JF, Fowkes FG (2003) Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 25:1–5

    Article  CAS  PubMed  Google Scholar 

  8. Heit JA (2006) The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 21:23–29

    Article  PubMed  Google Scholar 

  9. Goldhaber SZ (2004) Pulmonary embolism. Lancet 363:1295–1305

    Article  PubMed  Google Scholar 

  10. Kyrle PA, Eichinger S (2005) Deep vein thrombosis. Lancet 365:1163–1174

    Article  PubMed  Google Scholar 

  11. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281:2189–2197

    Article  CAS  PubMed  Google Scholar 

  12. Diel IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475–482

    CAS  PubMed  Google Scholar 

  13. Adami S, Zamberlan N (1996) Adverse effects of bisphosphonates. A comparative review. Drug Safety 14:158–170

    Article  CAS  PubMed  Google Scholar 

  14. Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY (2009) Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int. doi:10.1007/s00198-009-1050-7

  15. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L (2009) Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos Int. doi:10.1007.s00198-009-1091-y

  16. Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287:2398–2399

    Article  CAS  PubMed  Google Scholar 

  17. Glynn RJ, Rosner B (2005) Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 162:975–982

    Article  PubMed  Google Scholar 

  18. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019–1028

    CAS  PubMed  Google Scholar 

  19. Suissa S (2008) Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 168:329–335

    Article  PubMed  Google Scholar 

  20. Samama MM (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160:3415–3420

    Article  CAS  PubMed  Google Scholar 

  21. Hagg S, Spigset O (2002) Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 16:765–776

    Article  PubMed  Google Scholar 

  22. Zornberg GL, Jick H (2000) Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 356:1219–1223

    Article  CAS  PubMed  Google Scholar 

  23. Rothman KJ, Greenland S (2008) Modern epidemiology (third edition). Philadelphia, PA: Lippencott, pp 435–457

  24. Sorensen HT, Lash TL, Rothman KJ (2006) Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 44:1075–1082

    Article  PubMed  Google Scholar 

  25. Thygesen SK, Christiansen SF, Lash TL, Sørensen HT (2009) Predictive value of coding of diagnoses in the Charlson Index in the Danish National Registry of Patients. Pharmacoepidemiol Drug Saf 18:189

    Google Scholar 

  26. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr (1994) The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154:861–866

    Article  PubMed  Google Scholar 

  27. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med 342:1953–1958

    Article  CAS  PubMed  Google Scholar 

  28. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64S–94S

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark

    A. L. Lamberg, E. Horvath-Puho, S. Christensen & H. T. Sørensen

Authors
  1. A. L. Lamberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Horvath-Puho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. T. Sørensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. L. Lamberg.

Additional information

Financial support

The study received financial support from Department of Clinical Epidemiology’s Research Foundation.

Appendix

Appendix

Table 4 International Classification of Diseases (ICD) codes
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamberg, A.L., Horvath-Puho, E., Christensen, S. et al. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study. Osteoporos Int 21, 1911–1917 (2010). https://doi.org/10.1007/s00198-009-1143-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1143-3

Keywords

Search

Navigation